Ivantis Reports 2-Year Hydrus Trial Data

■ Ivantis has reported 24-month data from its 152-patient COMPARE trial. In this study, investigators compared the Hydrus microstent against 2 large-diameter iStent devices in treating open-angle glaucoma in a standalone procedure encompassing patients with mild to late moderate-stage disease. Results showed that 38% of patients treated with the Hydrus procedure were medication free, compared to 18.7% of patients in the iStent groups. Medication use was reduced by 1.3 medications, or 52%, on average for Hydrus patients, while iStent patients saw reductions of 0.8, or 29%, Ivantis reported. GP